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Abstract
We explored the characteristics and motivations of people who, having obtained their
genetic or genomic data from Direct-To-Consumer genetic testing (DTC-GT) companies,
voluntarily decide to share them on the publicly accessible web platform openSNP. The
study is the first attempt to describe open data sharing activities undertaken by individuals
without institutional oversight. In the paper we provide a detailed overview of the distribution
of the demographic characteristics and motivations of people engaged in genetic or geno-
mic open data sharing. The geographical distribution of the respondents showed the USA
as dominant. There was no significant gender divide, the age distribution was broad, educa-
tional background varied and respondents with and without children were equally repre-
sented. Health, even though prominent, was not the respondents’ primary or only motivation
to be tested. As to their motivations to openly share their data, 86.05% indicated wanting to
learn about themselves as relevant, followed by contributing to the advancement of medical
research (80.30%), improving the predictability of genetic testing (76.02%) and considering
it fun to explore genotype and phenotype data (75.51%). Whereas most respondents were
well aware of the privacy risks of their involvement in open genetic data sharing and consid-
ered the possibility of direct, personal repercussions troubling, they estimated the risk of this
happening to be negligible. Our findings highlight the diversity of DTC-GT consumers who
decide to openly share their data. Instead of focusing exclusively on health-related aspects
of genetic testing and data sharing, our study emphasizes the importance of taking into
account benefits and risks that stretch beyond the health spectrum. Our results thus lend
further support to the call for a broader and multi-faceted conceptualization of genomic
utility.
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Introduction
Genomic research promises major advances in our understanding of health and disease. In
parallel, sharing genomic data offers encouraging prospects to accelerate research by generat-
ing information-rich genome datasets. Such benefits, however, will only reach the general pop-
ulation if researchers and clinicians can access, make comparisons and seek patterns across
the genomes of a large number of individuals. Indeed, most studies require the aggregate of
genomic data from large cohorts of individuals, both healthy and diseased, before any health-
related utility can be established with reasonable confidence. However, numerous technical,
legal, and ethical bottlenecks hamper the exploitation of such data [1]. Moreover, due to the
diversity and fragmentation in health systems and medical databases, there is a lack of harmo-
nization of data formats, processing, analysis and data transfer, which often leads to incompat-
ibilities and lost opportunities for scientific advancement [2]. This difficulty in sharing genetic
data for research purposes is aggravated by the fact that despite much progress, genomic and
clinical data are still generally collected and studied in silos: by disease, by institution and by
states [3] Although international guidelines have facilitated sharing and generally take a pro-
portional risk approach, many countries have put in place strict provisions guiding interna-
tional sharing, and a few even prohibit it entirely [4]. Furthermore, while experts support
rigorous oversight and assessments of inter-lab reproducibility, they also caution that regula-
tion should not pose an excessive administrative burden on academic and smaller diagnostic
laboratories that are already saddled with burgeoning research expenses [5].
Despite such limitations, over the last few years, increasing amounts of genomic data have
been generated and became available for research purposes through a number of different
platforms. One of the first projects to address the need for large scale genomic data sharing
was the Personal Genome Project (PGP), which aimed at enrolling 100,000 participants [6].
Launched in 2005 under the umbrella of the Harvard Medical School, its network has since
expanded and now includes projects in Canada, the UK and Austria [7].The participants’
genomes are analysed by PGP and subsequent results, together with phenotypic data, are
made public. Another source of genetic data stems from Direct-To-Consumer genetic testing
(DTC-GT)–offered by companies like 23andMe, Family Tree DNA or Ancestry.com [8,9].
Thanks to the rapid growth of DTC-GT, data have become available for an increasingly broad
audience over the last decade. One project making use of this data is dna.land, which began
in 2015 at the New York Genome Center and to which DTC-GT costumers can upload their
own data [10]. As a result, the dna.land team can use the data for research purposes whereas
DTC-GT customers receive a genealogical analysis in return. The data and results, however,
are not publicly accessible.
An alternative to the above approaches, likewise making use of the rising numbers of
DTC-GTs, is openSNP [11]. Initiated in 2011, the platform allows individuals to contribute
diverse sets of DTC-GT results, along with phenotypic annotations about themselves. Specifi-
cally, users can share their DTC-GT results from micro-array based genotyping, which makes
up the vast majority of all data sets. Furthermore, users can upload VCF (variant call format)
files, which may include exomes and full genomes. Genomic and phenotypic data are subse-
quently openly available to anyone, without any limits or restrictions on the use of the data. In
that sense, the project combines both the open participation approach of dna.land and the
open data functionality of the PGP. But unlike the PGP and dna.land, openSNP is not affiliated
to an academic institution. Instead, it serves as a non-profit project that is run by a small group
of volunteers and is funded through individual donations, collected via an ongoing crowd-
funding campaign. Moreover, the licensing terms of openSNP do not restrict the reusing of
genetic data, as the users share their data by accepting their release in the public domain
Open sharing of genomic data: Who does it and why?
PLOS ONE | https://doi.org/10.1371/journal.pone.0177158 May 9, 2017 2 / 15
through the Creative Commons Zero framework. On the openSNP website, the agreement
thus states, “You agree that all data you upload to openSNP will be freely available online (well,
except your mail-address and password) under a Creative Commons Zero license. The data
can be viewed and downloaded through this webpage, RSS-feeds, and, in the future, perhaps
via an API or FTP. Although you can delete your data from openSNP, this does not guarantee
that someone else has not already created a backup of the data (who may re-publish the data
somewhere else)” [12]. Despite this radically open approach, the project has attracted more
than 5,000 registered users to date (2017-02-06), relying purely on social media and word of
mouth for recruiting. Since September 2011, users have uploaded over 3,000 data sets [13] and
interest in using them for scientific studies and commentary has continued to grow [14–17].
Given the concerns about genomic privacy, and specifically DTC-GT consumers’ privacy
risks, openSNP presents a case of special interest. What is original about the openSNP ap-
proach is that it attracts users willing to openly share their genomic data while accepting that
no protection of their privacy is on offer. Some users upload their data using pseudonyms;
others use their real names, and some even link their social media profiles to their openSNP
profiles. Research on DTC-GT consumers has so far focused on exploring motivations for
genomic testing, the perception of risk by DTC-GT users and the impact of testing on consum-
ers’ lives and behavior. And whereas earlier studies have also investigated the motivations and
attitudes of individuals toward genetic and genomic data sharing [18–25], this is the first study
of its kind to describe individuals who have decided to share their data publicly and without
any institutional oversight. Our study describes openSNP users’ characteristics, their motiva-
tions for sharing as well as their views about privacy and explores what drives their choice to
share their genomic data in the public domain.
Materials and methods
In order to understand the openSNP users’ background, main interests and impetus to openly
share their genomic data and their attitudes on issues of privacy, an anonymous online survey
was emailed to 3884 openSNP users, yielding a 14.16% overall response rate (n = 550; 323 male,
221 female, 1 other, 5 n/a). This response rate is consistent with other recent online-based sur-
veys [26]. The survey included both closed and open-ended questions on a) the respondents’
demographic information; b) their openness to and willingness to share genetic data; and c) the
privacy-related concerns they might have regarding their data sharing or potential data sharing
in the future. The respondents were offered a non-response (skip) option for all questions and
analyses were conducted using descriptive and inferential statistics for the closed answers.
We further examined the associations between the respondents’ motivations to participate
in genetic and genomic data sharing research and some of their basic demographic character-
istics by using linear and logistic regression. Our model is based on a linear regression using a
variable on how strongly the respondents feel about contributing to advancement of medical
research as the dependent variable, controlling for such covariates as gender (male, female or
other), having children and the respondents’ highest level of education (ranging across four
categories from high school to doctorate levels). We used significance at the level of p< 0.05
in the analysis, which was conducted employing Stata/SE 12.0.
The Zurich Cantonal Ethics Commission waived review of this project as it involved
research with anonymous data.
Results
The majority of respondents (60.33%) came from the USA, followed by Canada (5.17%) and
the UK (4.61%). A further 7 countries each contributed between 4 and 1% of our respondents,
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namely Australia (3.32%), France (2.21%), Switzerland (2.21%), Russia (2.03%) and Italy
(1.48%) (Fig 1). The remainder were scattered across some 41 countries, from all continents
except Antarctica. The age distribution was broad, with the youngest respondents being born
in 1995 and the oldest respondent in 1938 (Fig 2). 59.27% of respondents were men and
49.08% of all the respondents had children (see Table 1).
Most respondents (74.30%) were not engaged with biomedical research; 15.57% were or
had been research participants while 14.63% were involved in biomedical research in a profes-
sional capacity. The educational composition and engagement in biomedical research by gen-
der is illustrated in Table 2.
Many of the respondents had used more than one genome profiling and ancestry compa-
nies. 23andMe was the most popular with 412 users, followed by Ancestry.com and Family
Tree DNA both with around 80 users. Numerous other platforms, including National Geo-
graphic and the Personal Genome Project, had been chosen, albeit to a considerably lesser
degree. Participants were asked to rank three options for their interest in being tested: health,
ancestry or as a contribution to research. As a result, 46.41% gave ancestry as their first option,
followed by health (41.56%) whereas contribution to research trailed third (14.35%). Other
reasons included genealogy, locating relatives and curiosity. When asked if DNA testing had
helped them improve their health or life style, around a third checked not at all (33.20%) or to
a small extent (38.49%) while 19.14% recorded a moderate and 9.16% a large improvement.
Concerning motivations to share genetic and genomic data on openSNP, our preliminary
observational results show that 86.05% indicated wanting to learn about themselves as relevant
or very relevant, followed by contributing to the advancement of medical research (80.30%),
wanting to help improve the predictability of genetic testing and considering it fun to explore
genotype and phenotype data (76.02% and 75.51%, respectively). The distribution of reasons
to participate in genetic data sharing by gender is illustrated in Table 3.
Most respondents had uploaded their genotypic raw data to openSNP fairly recently, in
many cases in the previous few months. Of the 550 study subjects, 178 did not specify how
often they had visited the website, whereas 101 (27.15%) reported they had only done so for
Fig 1. World map of survey population.
https://doi.org/10.1371/journal.pone.0177158.g001
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uploading data and 181 (48.66%) a couple of times since then. Meanwhile, 78 (20.97%) stated
that they visit occasionally, although only 12 respondents (3.23%) reported to visit the website
regularly.
What is more, the respondents’ interest in uploading other data beyond their raw genotype
data was limited. Only 35.83% of respondents had added phenotypes, but a further 49.72%
thought they would do so in the future. Nonetheless, some users had created their own pheno-
types by adding new trait questions to the openSNP database. Of the 5082 currently registered
users, 1041 (20.48%) shared their eye color, 675 (13.28%) their hair color, 257 (5.06%) their
political ideology, 40 (0.79%) their colon cancer status and 23 (0.45%) their status for heredi-
tary breast and ovarian cancer [27].
In our basic exploratory model we also tested whether or not respondents identified their
willingness to contribute to the advancement of medical research as their main priority for
participating in genetic and genomic data sharing. Our model’s results are presented in
Table 4, where we demonstrate that a) having children and b) the level of education have a
significant effect on the relevance of the participants’ wish to contribute to medical research
as a motivation for sharing their genetic data. Our results show that both having children and
a master’s degree reduce the relevance of wanting to contribute to medical research in our
participants.
Since our explorative results indicate that education and having children render the contri-
bution to the advancement of medical research less relevant for our participants’ motivation to
Fig 2. Age histogram of survey population.
https://doi.org/10.1371/journal.pone.0177158.g002
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participate in genetic and genomic data sharing, perhaps, future research attempts should be
aimed at investigating how individuals’ motivation changes with increasing education or when
having children.
With regard to privacy and confidentiality concerns, 73.17% of the respondents stated that
they had not read or had only read quickly over the terms and conditions for sharing their
data while registering on openSNP. Table 5 shows how accurately the participants read the
terms and conditions of the openSNP platform by gender and education, respectively.
A large majority of participants thought it was rather likely (34.39%), or very likely
(52.02%), that their genetic data could never be fully deleted. In addition, 65.99% of the
respondents deemed it likely that their data will be used for purposes other than research.
Nearly half of the respondents also thought it rather likely (34.69%) or very likely (13.12%)
that their data would be employed for research of which the respondents themselves would
not approve. Moreover, more than half of the respondents stated they would be not at all
(26.45%) or rather little concerned (37.79%) with that prospect. However, the majority would
be rather concerned (19.88%) or very concerned (38.60%), were an employer to use their
genotype data to their disadvantage. Asking the same question with regard to insurance com-
panies, 45.88% would be very concerned or at least rather concerned (23.24%), although the
vast majority considered this to be a rather unlikely (38.89%) or very unlikely (48.54%) sce-
nario in case of the employer, with similar results for the insurance company (rather unlikely
37.76% or very unlikely 27.14%). Table 6 presents an overview of the respondents’ views on
privacy and genomic data protection.














Table 2. Participants’ education and engagement in biomedical research by gender.
Education Women (%) Men (%) Total (N)
Pre-high school 0.45 2.80 10
High school 24.43 18.07 113
Bachelor’s degree 45.70 33.64 210
Postgraduate degree 29,41 45,48 213
Engaged in biomedical research. . . Women (%) Men (%) Total (N)
. . .as a professional 10.36 16.62 78
. . .as a participant 15.32 14.80 83
Not engaged 74.32 68.58 396
https://doi.org/10.1371/journal.pone.0177158.t002
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Discussion
The constantly decreasing cost of large-scale genotyping and genome sequencing has sustained
the burgeoning growth of the personal genomic industry. This phenomenon has attracted a lot
of research attention. While most empirical research on personal genomics has focused on the
attitudes of early DTC-GT users, however, the present study aimed at shedding light on the
characteristics and motivations of people who, having obtained their genetic or genomic data
from a DTC-GT company, voluntarily decide to share them on a fully accessible platform like
openSNP. Our findings highlight the diversity and range of DTC-GT consumers. The geo-
graphical distribution of the respondents showed the USA and other mainly English speaking
countries as predominant. The age distribution was broad and there was no marked gender
divide. Educational background was varied, with the median distribution towards a slightly
more highly educated population. These characteristics do not corroborate other research,
which suggests that, as a rule, individuals purchasing DTC genetic and genomic test are highly
educated, middle aged users [28,29].
Data sharing and genomic utility
The emergence of direct-to-consumer genetic and genomic tests seems to reflect the interest
in genetic testing amongst a diverse array of users. Indeed, DTC-GT companies have rapidly
Table 3. Motivation to participate in genetic data sharing by gender.
. Not at all
relevant
Somewhat relevant Relevant / very relevant Total
Women (%) I wanted to learn more about myself 1.41 9.15 89.44 100.00
Men (%) 3.54 12.63 83.83 100.00
Total (N) 9 38 293 340
Women (%) Contribute to the advancement of
medical research
5.63 12.68 81.69 100.00
Men (%) 6.19 14.43 79.38 100.00
Total (N) 20 46 270 336
Women (%) Help improve the predictability of
genetic testing
7.75 14.79 77.46 100.00
Men (%) 8.67 16.33 75 100.00
Total (N) 28 53 257 338
Women (%) Consider it fun to explore genotype
and phenotype data
6.34 19.72 73.94 100.00
Men (%) 8.63 14.72 76.65 100.00
Total (N) 26 57 256 339
https://doi.org/10.1371/journal.pone.0177158.t003
Table 4. Having children and the level of education effect on the relevance of wanting to contribute to advancement of medical research among
open SNP participants.
Coef. Robust SE T p value 95% Conf. Interval
Gender -0.13 0.10 -1.35 0.177 -0.33 0.06
Having children -0.23 0.10 -2.30 0.022* -0.43 -0.03
Education
High school -0.15 0.24 -0.63 0.531 -0.62 0.32
Undergraduate -0.28 0.23 -1.22 0.222 -0.73 0.17
Graduate -0.47 0.24 -1.97 0.050* -0.94 0.00
Doctorate -0.10 0.25 -0.38 0.706 -0.59 0.40
* N = 336, R-squared = 0.042
https://doi.org/10.1371/journal.pone.0177158.t004
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generated growing consumer interest by advertising health-related and ancestry tests. Both in
the case of tests providing health-related information and genetic ancestry testing, however,
the scientific validity of the information released to consumers has been a major issue of
debate. In the field of health-related DTC-GT, such controversies eventually contributed to the
Food and Drug Administration (FDA) requesting 23andMe to discontinue their health-related
Personal Genome Service in 2013, as the company had failed to provide answers about the ana-
lytical and clinical validity of their services [30]. Two years later, 23andMe gained approval
from the FDA to market a carrier test for Bloom syndrome only [31] and the company subse-
quently went back on the market with one-quarter of their initial tests.
In light of these events, the risks and benefits of DTC health testing must be carefully
weighed, as today they remain far from clear. By and large, the majority of arguments for
and against direct-to-consumer genomic tests revolve around two issues: first, whether the
tests bring any personal or clinical utility and, second, whether the commercial availability of
such tests constitutes a threat to consumers or, rather, an opportunity for the cultivation of
Table 5. How accurately the respondents have read the terms and conditions of the openSNP platform by gender and education (in %).
Not at all I only read them over
Quickly
Carefully Total
By gender Women (%) 28.57 55.36 16.07 100
Men (%) 51.43 32.86 15.71 100
Total (N) 52 54 20 126
By education Pre-high school (%) 0 0 100 100
High school (%) 45 50 5 100
Bachelor’s (%) 38.78 42.86 18.37 100
Master’s (%) 35.71 50.00 14.29 100
PhD (%) 50.00 32.14 17.86 100
Total (N) 52 54 20 126
https://doi.org/10.1371/journal.pone.0177158.t005
Table 6. Respondents’ beliefs on the likelihood of data being fully deleted or misused by third parties and how concerned they would be about it.
Very unlikely Rather unlikely Rather likely Very likely Total
Can your data never be fully deleted? Percent 2.31% 11.27% 34.39% 52.02% 100%
Absolute 8 39 119 180 346
Will your data be used to do research that you would
not approve of?
Percent 14.87% 37.32% 34.69% 13.12% 100%
Absolute 51 128 119 45 343
Will your data be used to your disadvantage by an
employer?
Percent 48.54% 38.89% 9.06% 3.51% 100%
Absolute 166 133 31 12 342
Will your data be used to your disadvantage by an
insurance company?
Percent 27.14% 37.76% 23.60% 11.50% 100%
Absolute 92 128 80 39 339










If your data would be used to do research you would
not approve of?
Percent 26.45% 37.79% 22.38% 13.37% 100%
Absolute 91 130 77 46 344
If your data would be used to your disadvantage by an
employer?
Percent 23.68% 17.84% 19.88% 38.60% 100%
Absolute 81 61 68 132 342
If your data would be used to your disadvantage by an
insurance company?
Percent 15.00% 15.88% 23.24% 45.88% 100%
Absolute 51 54 79 156 340
https://doi.org/10.1371/journal.pone.0177158.t006
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individual autonomy [32]. With regard to personal or clinical utility, preliminary findings sug-
gest that the health benefits envisioned by DTC-GT companies (e.g. significant improvements
in positive health behaviors) have not materialized to date [33,34]. Studies investigating the
test data of the services further confirm that the tests have little predictive power and do not
measure genetic risk appropriately [35]. Moreover, clinical and behavioral effects of genetic-
risk disclosure have generally been reported to be minor or have tended to yield mixed results
[36]. Given the absence of clear evidence for clinical utility or health benefits, DTC-GT pro-
ponents have put forward a broader case for societal benefits [37]. Alternatively, scientists
involved in genetic research have stressed that the usefulness of genetic data lies in its crowd-
sourcing potential [38] and in having all data in one network [39]. Furthermore, the research-
ers behind the Personal Genome Project claim to have demonstrated that it is feasible for a
research study to publicly share combined genomic and health data. They also found that
when engaged in a participatory manner, contributors were highly motivated and volunteered
their time and efforts to help create that data [40]. Other studies have also shown that users are
indeed interested in DTC-GT in order to contribute to scientific research [41]. Our study sup-
ports this claim.
Given the uncertainties regarding the direct clinical benefits of DTC genetic testing, it
could be hypothesized that individuals who publicly share their DTC-GT data may be seeking
to extract other types of utility. This hypothesis is supported by our results, as a large majority
of our respondents indicated that contributing to the advancement of medical research, want-
ing to help improve the predictability of genetic testing and considering it fun to explore geno-
type and phenotype data were relevant or very relevant motivations to share their data on
openSNP.
Above all, however, our results suggest that health, even though prominent, did not seem to
be the respondents’ primary or only motivation to be tested and share their data. In fact, we
are dealing with a generally healthy population of respondents. And while several areas have
been specifically articulated by the respondents (ancestry, scientific curiosity, health, contrib-
uting to research, nutrition) ancestry was most commonly mentioned in answers to questions
on why users got tested in the first place and decided to share their data on openSNP. These
results are consistent with the findings of a recent study on the motivations of DTC-GT user’s,
which showed that the vast majority of users reported good to excellent health and that non-
medical information was of equal or greater interest to consumers [42].
Ancestry-related motivations deserve a closer look. Whereas it is generally assumed that
purchasing genetic ancestry tests has a mainly recreational utility, consumers may also have
other valuable personal motivations, as for example finding relatives or documenting one’s
family history. Such uses, however, do not come without potential risks. Discovering bonds of
kinship can be destabilizing, for both the person that purchased the test and those who get to
be identified as relatives by someone they have never met before. In particular, discovering sib-
lings through mitochondrial DNA or Y chromosome SNPs carries the potential to alter peo-
ple’s perception of their personal identity and can, in consequence, turn out to be a source of
deep psychological distress for individuals and their families alike.
Moreover, consumers also use genetic ancestry testing to learn about their racial and ethnic
background–as in the case of African-Americans who seek for the geographical roots that
slavery has obscured [43]. Yet when such uses stem from the need to negotiate one’s member-
ship into a given social group, they may also lead to very tangible consequences, for instance
with regard to college/university enrolment or employment. Establishing ethnicity through
genotyping of a few allelic loci, however, is considerably less accurate than many consumers
believe [44] and it is riddled with questionable assumptions about race and DNA. In particular,
connecting racial and ethnic classifications to DNA obscures the historical, political and
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geographic determinants of such classifications. Finally, DTC genetic ancestry testing also
lends itself to questionable political uses, as in the case of the Hungarian MP who resorted to a
DTC-GT company to prove he does not have any “Roma or Jewish genes” [45]. Publicly shar-
ing genetic and genomic data may thus amplify both the utilities and the risks of genetic ances-
try testing.
Data sharing and privacy risks
Over the past decade, IT companies have become the enablers and custodians of crucial tech-
nologies. They are increasingly operating as gatekeepers, and as a result occupy critical data
junctions. DTC-GT companies are no exception. Indeed, genetic tests lead to crucial data and
with that to new forms of power [46]. Therefore, the proliferation of DTC testing raises press-
ing questions about whether commercial firms are gaining access to health data without the
necessary accountability. This is consistent with the circumstance that whereas the testing
companies’ front-end activity consists in selling individual genetic tests online, their back-end
business model involves amassing large privately owned genetic databases that they can exploit
commercially [47]. As a result the privatization of genetic data has elicited novel anxieties and
continues to raise many concerns regarding privacy, liability and consent [48,49]. As we
report, however, whereas most of our respondents were well aware of the risks of their involve-
ment in open genetic data sharing and consider the possibility of direct, personal repercussions
troubling, they estimated the risk to be negligible. Our findings undermine a frequently enter-
tained argument about the waning value that people allegedly attach to privacy in the era of
connectivity and social media [50–52]. Quite to the contrary, our study shows that individuals
are still concerned about privacy protection, even if they decide to share their genetic and
genomic data publicly. It appears as though the respondents’ decision to openly share genetic
data involves a certain compromise: to move forward in research, which is indeed a com-
monly-mentioned motivation for openSNP users, is to take a risk in the privacy and data-pro-
tection realm. Nonetheless, those who decide to take the risk, do so under the assumption that
the risk is reasonably acceptable [53].
Certainly, understandings of risks can differ, particularly when–as in the case of genomics–
there is no clear consensus about the likelihood of those risks. While some argue that there is
very little holding testing companies to account, or that individual customers’ healthcare insur-
ance premiums could go up, our survey has shown that health-related concerns are only of sec-
ondary interest to most customers who openly share their data. We thus expect that privacy
concerns will not undermine the DTC testing industry, despite the regulatory constraints that
emerged over the last few years to restrict the provision of health-related information to
consumers.
Data sharing and the right to participation
Until recently, genetic tests could only be obtained through healthcare providers. The latter
would commission the appropriate analysis from a laboratory, collect and dispatch the samples
and interpret the outcomes without involving the patient. Traditional research institutions, in
turn, used to be the only players at the forefront of genetic research. Yet over the past decade,
interest in genetic testing has spread far and wide beyond the conventional research realms,
and often with growing intensity. Under a broadly conceived right to participation, companies
have succeeded in accumulating health data from huge numbers of consumers, through DTC
genetic tests sold online as well as through health and wellness apps and self–tracking devices
[54]. In this respect, individuals, whose lives are ever more moulded by a wide range of mobile
health applications or connected devices, are increasingly confronted by what has been called
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a perfect storm of information [55] to which they constantly contribute. Meanwhile, individu-
als keep gaining access to the technological means that allow them to take a more proactive
role not only in their own health care but also as participants in the research process itself. Fur-
thermore, the DTC-GT process commonly bypasses the involvement of healthcare profession-
als both upstream and downstream, as confirmed by data showing that the majority of subjects
who had purchased a DTC-GT did not share their results with a health-care professional [56].
Nevertheless, some expect the proportion of users who share their results with a health-care
professional to rise, once the opportunity presents itself or results become more pertinent to
patients’ medical needs [57].
It has been argued that such recent developments have ushered in an era of increased scien-
tific involvement for ordinary citizens, therefore opening new forms of engagement with sci-
ence beyond the rather narrow possibilities afforded by participation in clinical research. In
that sense, some citizens are operating outside of, or even antagonistically to, the traditional
research environment–a phenomenon that has led some patients’ constituencies to conceptu-
alize data sharing as a form of “disobedience” [58]. Arguably, platforms like openSNP stretch
the meaning of participation a step further, as they enable users to mobilize their own data for
research purposes. This feature, other than reshaping the notion of participation as an individ-
ual right, may also prelude to societal obligations to even promote such a right of individuals
to use their personal and health data to conduct biomedical research outside the traditional sci-
entific setting. While science used to be characterized by exclusivity, with traditional gatekeep-
ers occupying all the critical junctions, the realm of genetic testing appears to undermine the
scientific community’s once unchallenged authority. The convergence between, on the one
hand, science and regulation and, on the other hand, a large public who traditionally held lim-
ited biomedical knowledge and power, begs further exploration.
Conclusion
Throughout this paper we have shown that DTC-GT consumers who openly share their
genetic data–far from focusing exclusively on the health-related aspects of genetic and geno-
mic testing–are animated by diverse purposes and concerns. The present study thus contrib-
utes to a broader understanding of the issues pertaining to genetic and genomic data sharing
and supports the idea that genomic utility should be understood across a variety of domains
and perspectives. Instead of focusing exclusively on health-related aspects of genetic testing
and data sharing, our study thus highlights that it is crucial to consider benefits, risks and
developments that stretch beyond the health spectrum. Our findings support the call for a
broader and multi-faceted conceptualization of genomic utility, one that pays due attention to
the value users attach to being tested and to sharing data also in terms of contributing to the
common good of research or seeking connection to other people and places [59]. As a conse-
quence, such non-medical utilities, together with non-medical dis-utilities of the sort we men-
tioned above, should be an integral part of the ethical and regulatory debates surrounding
DTC genetics and the practice of data sharing [60].
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